Diagnósticos en el Cáncer de Pulmón de Células No Pequeñas (CPCNP) y Clasificación TNM (CPCNP): 2do Consenso Nacional de la Sociedad Panameña de Oncología (SPO). (Mesa 2)
[Diagnósticos en el Cáncer de Pulmón de Células No Pequeñas (CPCNP) y Clasificación TNM (CPCNP): 2do Consenso Nacional de la Sociedad Panameña de Oncología (SPO). (Mesa 2)]Tarsicio Perea1, B Isaza2, H Tapia3, O Pinzón3, Y González4, V Williams5, M Leonis2, A Crismatt3
1. Complejo Hospitalario Metropolitano “Dr. Arnulfo Arias Madrid” (CH.Dr.A.A.M.) & Instituto Oncológico Nacional.; 2. Complejo Hospitalario Metropolitano; 3. Instituto Oncológico Nacional; 4. Hospital Santo Tomás; 5. Hospital Amador Guerrero.
Descargas
Resumen
Resumen
En todo paciente con sospecha de cáncer de pulmón la obtención de tejido para su análisis patológico es de vital importancia previo al inicio de cualquier tratamiento. Sin embargo, en muchas ocasiones la obtención de tejido se puede convertir en un verdadero reto ya que las lesiones no siempre son accesibles por broncoscopia y la tasas de complicaciones de la biopsia percutánea guiada por Tomografía pueden llegar hasta el 15 % en ciertas poblaciones de alto riesgo (adultos mayores, fumadores y con enfermedad pulmonar obstructiva crónica)[1].
El objetivo de este consenso es orientar al personal de salud sobre los pasos a seguir para el diagnóstico oportuno del nódulo pulmonar solitario y la enfermedad con características francas de malignidad (Localmente avanzada y metastásica) para su pronta referencia al grupo de Manejo Multidisciplinario.
[Diagnostic Studies in Non Small Cell Lung Cancer (NSCLC) and TNM Classification (CPCNP): 2nd National Consensus of the Panamanian Oncology Society (SPO)]
Abstract
In all patients with suspected lung cancer, obtaining tissue for pathological analysis is of vital importance prior to the initiation of any treatment. However, tissue procurement can often become a real challenge since the lesions are not always accessible by bronchoscopy and the complication rates of CT-guided percutaneous biopsy can reach up to 15% in certain high-risk populations risk (elderly, smokers and with chronic obstructive pulmonary disease)[1].
The objective of this consensus is to guide health personnel on the steps to follow for the timely diagnosis of the solitary pulmonary nodule and the disease with frank characteristics of malignancy (Locally advanced and metastatic) for its early reference to the Multidisciplinary Management group.
Abstract
Resumen
En todo paciente con sospecha de cáncer de pulmón la obtención de tejido para su análisis patológico es de vital importancia previo al inicio de cualquier tratamiento. Sin embargo, en muchas ocasiones la obtención de tejido se puede convertir en un verdadero reto ya que las lesiones no siempre son accesibles por broncoscopia y la tasas de complicaciones de la biopsia percutánea guiada por Tomografía pueden llegar hasta el 15 % en ciertas poblaciones de alto riesgo (adultos mayores, fumadores y con enfermedad pulmonar obstructiva crónica)[1].
El objetivo de este consenso es orientar al personal de salud sobre los pasos a seguir para el diagnóstico oportuno del nódulo pulmonar solitario y la enfermedad con características francas de malignidad (Localmente avanzada y metastásica) para su pronta referencia al grupo de Manejo Multidisciplinario.
[Diagnostic Studies in Non Small Cell Lung Cancer (NSCLC) and TNM Classification (CPCNP): 2nd National Consensus of the Panamanian Oncology Society (SPO)]
Abstract
In all patients with suspected lung cancer, obtaining tissue for pathological analysis is of vital importance prior to the initiation of any treatment. However, tissue procurement can often become a real challenge since the lesions are not always accessible by bronchoscopy and the complication rates of CT-guided percutaneous biopsy can reach up to 15% in certain high-risk populations risk (elderly, smokers and with chronic obstructive pulmonary disease)[1].
The objective of this consensus is to guide health personnel on the steps to follow for the timely diagnosis of the solitary pulmonary nodule and the disease with frank characteristics of malignancy (Locally advanced and metastatic) for its early reference to the Multidisciplinary Management group.
Citas
[1] Wiener RS, Schwartz LM, Woloshin S, et al. Population-based risk for complications after transthoracic needle lung biopsy of a pulmonary nodule: an analysis of discharge records. Ann Intern Med 2011; 155: 137–144.
[2] Truong MT, Ko JP, Rossi SE, et al. Update in the evaluation of the solitary pulmonary nodule. Radiographics. 2014; 34 (6):1658-79.
[3] Patel VK, Naik SK, Naidich DP et al. A practical algorithmic approach to the diagnosis and management of solitary pulmonary nodules: part 2: pretest probability and algorithm. Chest 2013; 143: 840–846.
[4] The diagnosis and treatment of lung cancer. London: National Institute for Health and Clinical Excellence. Nice Clinical Guideline, 121; 2011.
[5] De Hoop B, De Boo DW, Gietema HA, et al. Computer- aided detection of lung cancer on chest radiographs: effect on observer performance. Radiology. 2010; 257: 532-40.
[6] Gould MK, Donington J, and Lynch WR, et al. Evaluation of individuals with pulmonary nodules: When is it lung cancer? Diagnosis and management of lung cancer, 3rd ed.: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013 May; 143 (5 Suppl):e93S-120S.
[7] Harders SW, Madsen HH, Rasmussen TR, et al. High resolution spiral CT for determining the malignant potential of solitary pulmonary nodules: refining and testing the test. Acta Radiol. 2011; 52: 401-09.
[8] Kishi K, Homma S, Kurosaki A, Motoi N, Kohno T, Nakata K, et al. Small lung tumors with the size of 1cm or less in diameter: clinical, radiological, and histopathological Characteristics. Lung Cancer. 2004; 44: 43-51.
[9] Pinilla I, Gómez León N. The usefulness of PET/CT in lung cancer. Radiología. 2009; 51: 248-60.
[10] Opoka L, Kunikowska J, Podgajny Z, et al. Accuracy of FDG PET/CT in the evaluation of solitary pulmonary lesions –own experience. Pneumol Alergol Pol. 2014; 82:198-205.
[11] Seemann MD, Seemann O, Luboldt W, et al. Differentiation of malignant from benign solitary pulmonary lesions using chest radiography, spiral CT and HRCT. Lung Cancer. 2000; 29: 105-24.
[12] Taus A, Aguiló R, Curull V, et al. Impacto del 18-FDG PET-TAC en el abordaje terapéutico del cáncer de pulmón no microcítico. Arch Bronconeuml. 2014; 50:99-104.
[13] Silvestri GA, Gonzalez AV, Jantz MA, et al. Methods for Staging Non-small Cell Lung Cancer: Diagnosis and management of lung cancer, 3rd ed.: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013; 143 Suppl: e211S-50S.
[14] De Leyn P, Dooms C, Kuzdzal J, et al. Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small cell lung cancer. Eur J Cardiothorac Surg. 2014; 45:787-98.
[15] Alonso Moralejo R, Sayas Catalán J, García Luján R, et al. Utilidad de la tomografía por emisión de positrones en la detección de metástasis ocultas extra torácicas en el carcinoma broncogénico no células pequeñas. Arch Bronconeumol. 2010; 46: 238-43.
[16] Na F, Wang J, Li C, et al. Primary tumor standardized uptake value measured on F18-fluorodeoxyglucose positron emission tomography is of prediction value for survival and local control in non-small-cell lung cancer receiving radiotherapy: Meta-Analysis. J Thorac Oncol. 2014; 9:834-42.
[17] Vansteenkiste J, Crinò L, Dooms C, et al. 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up. Ann Oncol. 2014; 25:1462-74.
[18] D’Urso V, Doneddu V, Marchesi I, et al. Sputum analysis: non-invasive early lung cancer detection. J Cell Physiol. 2013; 228: 945-51.
[19] Rivera MP, Mehta AC, Wahidi MM. Establishing the diagnosis of lung cancer: Diagnosis and management of lung cancer, 3rd ed.: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013; 143 Suppl: e142S-65S.
[20] Du Rand IA, Barber PV, Goldring J, et al. BTS Interventional bronchoscopy guideline group. Summary of the British Thoracic Society guidelines for advanced diagnostic and therapeutic flexible bronchoscopy in adults. Thorax 2011 Nov; 66: 1014e5
[21] Le Jeune I, Baldwin D. Measuring the success of transbronchial needle aspiration in everyday clinical practice. Respir Med 2007; 101: 670e5.
[22] Gu P, Zhao YZ, Jiang LY, et al. Endobronchial ultrasound-guided transbronchial needle aspiration for staging of lung cancer: a systematic review and meta-analysis. Eur J Cancer 2009; 45: 1389e96.
[23] 60. Adams K, Shah P, Edmonds L, et al. Test performance of endobronchial ultrasound and transbronchial needle aspiration biopsy for mediastinal staging in patients with lung cancer: systematic review and meta-analysis. Thorax 2009; 64: 757e62.
[24] Daniels JMA, Sutedja TG. Detection and minimally invasive treatment of early squamous lung cancer. Ther Adv Med Oncol. 2013; 5: 235-48.
[25] Wiener RS, Schwartz LM, Woloshin S, et al. Population-based risk for complications after transthoracic needle lung biopsy of a pulmonary nodule: an analysis of discharge records: Ann Intern Med. 2011; 155: 137-42.
[26] Martín Díaz E, Arnau Obrer A, Martorell Cebollada Met al. La toracocentesis en la evaluación del cáncer de pulmón con derrame pleural. Arch Bronconeumol. 2002; 38: 479-84.
[27] Porcel JM, Esquerda A, Vives M, Bielsa S. Etiología del derrame pleural: análisis de más de 3.000 toracocentesis consecutivas. Arch Bronconeumol. 2014; 50: 161-5.
[28] Botana-Rial M, Leiro-Fernández V, Represas-Represas C, González-Piñeiro A, Tilve- Gómez A, Fernández-Villar A. Thoracic ultrasound-assisted selection for pleural biopsy with Abrams needle. Respir Care. 2013; 58:1949-54.
[29] Rami-Porta R, Ball D, Crowley J, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol.2007; 2: 593-602.
[30] Goldstraw P, Crowley J, Chansky K, et al; International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2007; 2: 706-14.
[31] Rusch VW, Crowley J, Giroux DJ, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the N descriptors in the forthcoming seventh edition of the TNM Classification for lung cancer. J Thorac Oncol. 2007; 2: 603-12.
[32] Postmus PE, Brambilla E, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for revision of the M descriptors in the forthcoming (seventh) edition of the TNM Classification of lung cancer. J Thorac Oncol. 2007; 2: 686-93.
[33] Shepherd FA, Crowley J, Van Houtte P, et al. The International Association for the Study of Lung Cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer. J Thorac Oncol. 2007; 2: 1067-77.
[34] Travis WD, Giroux DJ, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the inclusion of broncho-pulmonary carcinoid tumors in the forthcoming (seventh) edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2008; 3:1213-23.
[35] Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population based to a more “personalized” approach to cancer staging. CA: A Cancer Journal for Clinicians. 2017 Mar 1; 67(2):93-9.
Licencia
Derechos autoriales y de reproducibilidad. La Revista Médica de Panama es un ente académico, sin fines de lucro, que forma parte de la Academia Panameña de Medicina y Cirugía. Sus publicaciones son de tipo acceso gratuito de su contenido para uso individual y académico, sin restricción. Los derechos autoriales de cada artículo son retenidos por sus autores. Al Publicar en la Revista, el autor otorga Licencia permanente, exclusiva, e irrevocable a la Sociedad para la edición del manuscrito, y otorga a la empresa editorial, Infomedic International Licencia de uso de distribución, indexación y comercial exclusiva, permanente e irrevocable de su contenido y para la generación de productos y servicios derivados del mismo. En caso que el autor obtenga la licencia CC BY, el artículo y sus derivados son de libre acceso y distribución.
